| Fecha | Trimestre | Sesión | BPA (est → real) | Ingresos (est → reales) |
|---|---|---|---|---|
| 21 oct 2026Próximo | Q3 2026 | Antes de apertura | 2,21 | 834 M |
27 ago 2026
Are Wall Street analysts favoring West Pharmaceutical’s stock now as GLP-1 drugs gain prominence?
26 ago 2026
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences:
West Pharmaceutical Services has delivered a strong 43.0% return over the past year, yet current checks suggest the stock is not a clear bargain. The Discounted Cash Flow (DCF) intrinsic value estimate sits close to the market price, while market multiples lean expensive. The 43.0% one year return highlights how strongly West Pharmaceutical Services has rewarded shareholders over this period and raises the bar for future expectations. Expectations for steady demand in its drug delivery and...
20 ago 2026
Recent share performance and business backdrop West Pharmaceutical Services (WST) has drawn investor attention after a period where the stock returned 0.1% over the past month and 11.6% over the past 3 months, against a backdrop of steady reported operations. The company reports annual revenue of US$3.3b and net income of US$564.9m, supported by two primary segments. Proprietary Products contribute US$2.7b and West Vantage, which sits within that portfolio, adds US$600.6m. See our latest...
